{"nctId":"NCT02639247","briefTitle":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","startDateStruct":{"date":"2015-12-23","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":333,"armGroups":[{"label":"SOF/VEL/VOX","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL/VOX"]},{"label":"SOF/VEL","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]}],"interventions":[{"name":"SOF/VEL/VOX","otherNames":["Vosevi®","GS-7977/GS-5816/GS-9857"]},{"name":"SOF/VEL","otherNames":["Epclusa®","GS-7977/GS-5816"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* Chronic HCV infection (≥ 6 months)\n* Treatment experienced with a direct acting antiviral medication not including a NS5A Inhibitor for HCV\n* Use of protocol specified methods of contraception\n\nKey Exclusion Criteria:\n\n* Current or prior history of clinically significant illness that may interfere with participation in the study\n* Screening ECG with clinically significant abnormalities\n* Laboratory results outside of acceptable ranges at screening\n* Pregnant or nursing female\n* Chronic liver disease not caused by HCV\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"90.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"90.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ On Treatment","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"90.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.29","spread":"0.627"},{"groupId":"OG001","value":"-4.17","spread":"0.651"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.93","spread":"0.604"},{"groupId":"OG001","value":"-4.78","spread":"0.677"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.561"},{"groupId":"OG001","value":"-5.06","spread":"0.660"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.17","spread":"0.562"},{"groupId":"OG001","value":"-5.08","spread":"0.759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.17","spread":"0.559"},{"groupId":"OG001","value":"-5.09","spread":"0.727"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":182},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Back pain"]}}}